Adjuvant Therapy With Neratinib in HER2 Positive Early Breast Cancer

Summary

Human epidermal growth factor receptor 2 (HER2) positive breast cancer is a molecular subtype with high malignancy and high risk to recurrence and metastasis. After the appearance of anti-HER2 targeted drugs, the prognosis and survival of these patients were greatly improved. In addition to trastuzumab and pertuzumab, the use of tyrosine kinase inhibitor (TKI) can further improve the survival. The evidence of previous adjuvant TKI anti-HER2 therapy was mainly from ExteNET study. However, due to the limitations of the times, ExteNET research is based on the background of only trastuzumab targeted therapy. Nowadays, there is no evidence that trastuzumab combined patuzumab,use of T-DM1, followed by sequential neratinib can still obtain absolute benefits. Therefore, there is no standard for the use of neratinib in current clinical practice. Investigators want to explore, in the real world, the efficacy and safety of sequential use of naratinib in adjuvant therapy.

Eligibility

Inclusion Criteria:

* 1\) Patients with HER2 positive breast cancer who were diagnosed by core needle biopsy/operation in Peking University People's hospital;
* 2\) The patients were treated in our hospital and underwent radical resection with hospitalization records;
* 3\) Received standard anti-HER2 neoadjuvant/adjuvant therapy (trastuzumab, trastuzumab combined with pertuzumab, T-DM1)
* 4\) Has signed and agreed to participate in the PKUPH breast disease cohort study.

Exclusion Criteria:

* 1\) Lack of clinical and pathological data (such as imaging data and pathological data);
* 2\) Patients with metastatic breast cancer or bilateral breast cancer;
* 3\) Failure to perform radical surgery

Conditions3

Interventions1

Related trials

• Kadcyla And Neratinib for Interception of HER2+ Breast Cancer With Molecular Residual Disease — University Health Network, Toronto
• Personalized Medicine for Advanced Biliary Cancer Patients — UNICANCER
• I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer — QuantumLeap Healthcare Collaborative
• INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT) — Patrick Wen, MD
• Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2) — Scott R. Plotkin, MD, PhD
• Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal Cancer — H. Lee Moffitt Cancer Center and Research Institute
• Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers — Vanderbilt-Ingram Cancer Center
• Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers — Ruth O'Regan

Browse More Trials